How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

366 results for

Intraocular Carbonic Anhydrase Inhibitor

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema

and cataract constitute important causes of visual impairment in patients with diabetes. Cataract surgery in patients with diabetic retinopathy is associated with progression of retinopathy. Several modalities such as non-steroidal anti-inflammatory agents, carbonic anhydrase inhibitors, corticosteroids, hyperbaric oxygen, laser photocoagulation and vitrectomy with internal limiting membrane peeling have been tried for managing inflammatory cystoid macular edema. Intravitreal Triamcinolone Acetonide (TA (...) ; Genentech, South San Francisco, California), Bevacizumab (Avastin, Genentech) have been tried in an attempt to improve the visual results. Several modalities such as non-steroidal anti-inflammatory agents, carbonic anhydrase inhibitors, corticosteroids, hyperbaric oxygen, laser photocoagulation and vitrectomy with internal limiting membrane peeling have been tried for managing inflammatory cystoid macular edema13. Intravitreal Triamcinolone Acetonide (TA), a water insoluble steroid, has been shown

2012 Clinical Trials

182. Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil

Agonists Adrenergic alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors (...) in Intraocular Pressure (IOP) at 8 Weeks From Baseline (Prior Therapy). [ Time Frame: 8 weeks ] Intraocular pressure was measured by Goldmann applanation tonometry. Data for the worse eye were used for the efficacy analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your

2012 Clinical Trials

183. Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Pharmaceuticals International, Inc. More Information Go to Layout table for additonal information Responsible Party: Valeant Pharmaceuticals International, Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: CD-11-265 First Posted: November 7, 2012 Last Update Posted: April 4, 2019 Last Verified: March 2019 Additional relevant MeSH terms: Layout table for MeSH terms Ocular Hypertension Eye Diseases Brinzolamide Carbonic Anhydrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological (...) : available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Azopt 1% ophthalmic suspension Ophthalmic suspension Drug: Azopt 1% Azopt 1%, RLD Experimental: Brinzolamide 1% ophthalmic suspension ophthalmic suspension Drug: brinzolamide 1% ophthalmic suspension brinzolamide 1% ophthalmic suspension Outcome Measures Go to Primary Outcome Measures : Intraocular pressure (IOP) at baseline (Eligibility Visit 2) weeks and after treatment. [ Time Frame: 12 weeks ] Secondary Outcome

2012 Clinical Trials

184. Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH

ETDRS letters (equivalent to approximately 20/80 Snellen). Another ocular pathology (including severe dry eye) that may, in the opinion of the investigator, preventing the administration of an alpha-adrenergic agonist and/or an inhibitor of topical carbonic anhydrase (CAI). Intraocular surgery within the last 6 months. Laser eye surgery in the last 3 months. Any abnormality that prevents a reliable applanation tonometry. Any other condition including severe illness that would make the patient (...) brinzolamide Additional relevant MeSH terms: Layout table for MeSH terms Hypertension Glaucoma Glaucoma, Open-Angle Ocular Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Ophthalmic Solutions Latanoprost Brinzolamide Pharmaceutical Solutions Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

2012 Clinical Trials

185. Medical versus surgical interventions for open angle glaucoma. (Abstract)

two small trials in more severe OAG, that initial medication (pilocarpine, now rarely used as first line medication) is associated with more glaucoma progression than surgery. Beyond five years, there is no evidence of a difference in the need for cataract surgery according to initial treatment.The clinical and cost-effectiveness of contemporary medication (prostaglandin analogues, alpha2-agonists and topical carbonic anhydrase inhibitors) compared with primary surgery is not known.Further RCTs (...) was associated with marginally less visual field loss at five years than initial medication, (mean difference 0.74 dB (95% CI -0.00 to 1.48). Initial trabeculectomy was associated with lower average intraocular pressure (IOP) (mean difference 2.20 mmHg (95% CI 1.63 to 2.77) but more eye symptoms than medication (P = 0.0053). Beyond five years, visual acuity did not differ according to initial treatment (OR 1.48, 95% CI 0.58 to 3.81).From three trials in more severe OAG, there is some evidence that medication

2012 Cochrane database of systematic reviews (Online)

186. DIAGNOSIS AND TREATMENT OF GLAUCOMA—A Review of Recent Developments Full Text available with Trip Pro

of the hyperreactivity of the ciliary body and iris sphincter which it causes. These can be partly overcome by using pilocarpine first. Diamox is a carbonic anhydrase inhibitor that is effective when given orally. In many cases it produces at least a temporary lowering of tension in glaucomatous eyes, apparently by reducing the secretion of intraocular fluid. Its ultimate value in glaucoma remains to be seen. The cyclodiathermy operation which has been modified somewhat by Weekers has had a recent increase in use

1954 California Medicine

187. Pseudophakic pupillary-block glaucoma. Full Text available with Trip Pro

in obstructing aqueous flow at the pupil and peripheral iridectomy site was emphasised. Pitfalls in the diagnosis and management of this condition were reviewed. Methods of prevention and treatment were reviewed with emphasis on early mydriasis, along with carbonic anhydrase inhibitors and hyperosmotic agents as a primary medical treatment. Iridectomy, laser iridotomy, or transfixation of the iris was mentioned as a surgical treatment. (...) Pseudophakic pupillary-block glaucoma. Four cases of iris-supported pseudophakic pupillary-block glaucoma were presented. Pupillary-block glaucoma is the first postoperative complication seen following the implantation of an intraocular lens, and in our series occurred at an incidence of 3-8%. A short review was made of pupillary-block glaucoma with all types of intraocular lenses, with emphasis on the iris-supported lens. The role of inflammation, haemorrhage, and vitreous and lens material

1977 The British journal of ophthalmology

188. ACUTE ANGLE-CLOSURE GLAUCOMA: THE SECOND EYE: AN ANALYSIS OF 200 CASES Full Text available with Trip Pro

Carbonic Anhydrase Inhibitors therapeutic use Functional Laterality Glaucoma, Angle-Closure complications diagnosis etiology therapy Humans Intraocular Pressure Iridectomy Miotics therapeutic use Pilocarpine therapeutic use Time Factors Tonometry, Ocular Original DateCompleted: 20080111 1962 11 1 0 0 1962 11 1 0 1 1962 11 1 0 0 ppublish 18170827 PMC510261 AMA Arch Ophthalmol. 1952 Jun;47(6):695-716 14923028 Am J Ophthalmol. 1956 Nov;42(5):734-6 13372695 Br J Ophthalmol. 1957 Apr;41(4):193-9 13413134 (...) ACUTE ANGLE-CLOSURE GLAUCOMA: THE SECOND EYE: AN ANALYSIS OF 200 CASES 18170827 2009 08 28 2018 12 01 0007-1161 46 11 1962 Nov The British journal of ophthalmology Br J Ophthalmol ACUTE ANGLE-CLOSURE GLAUCOMA: THE SECOND EYE: AN ANALYSIS OF 200 CASES. 641-50 Lowe R F RF Melbourne, Australia. eng Journal Article England Br J Ophthalmol 0421041 0007-1161 0 Carbonic Anhydrase Inhibitors 0 Miotics 01MI4Q9DI3 Pilocarpine O3FX965V0I Acetazolamide OM Acetazolamide therapeutic use Acute Disease

1962 The British journal of ophthalmology

189. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. (Abstract)

A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Prostaglandin analogs are currently the first-line agents in the medical treatment of glaucoma. Frequently, more than one drug is needed to control intraocular pressure. Beta-blockers, topical carbonic anhydrase inhibitors, and alpha-adrenergic agonists are commonly used in addition to prostaglandin analogs. Topical carbonic anhydrase inhibitors are more effective in lowering intraocular pressure at trough than (...) alpha-adrenergic agonists. Although similarly effective as topical carbonic anhydrase inhibitors during the day, adequate nocturnal intraocular pressure reduction with beta-blockers is controversial. Three fixed combinations of prostaglandins with timolol (0.005% latanoprost with 0.5% timolol, 0.004% travoprost with 0.5% timolol, and 0.03% bimatoprost with 0.5% timolol) are available. Fixed-combination therapy has advantages over multi-drop, multi-bottle therapy in terms of patient convenience

1 Survey of Ophthalmology

190. Communications. Action of Atromid-S (clofibrate) on intra-ocular pressure. Full Text available with Trip Pro

Acetazolamide adverse effects Androsterone therapeutic use urine Animals Anticholesteremic Agents pharmacology therapeutic use urine Butyrates therapeutic use urine Carbonic Anhydrase Inhibitors Glaucoma drug therapy Humans Intraocular Pressure drug effects Rabbits 1968 11 1 1968 11 1 0 1 1968 11 1 0 0 ppublish 4972749 PMC506692 Lancet. 1967 Oct 21;2(7521):892 12389560 Trans Ophthalmol Soc U K. 1964;84:281-95 5227423 Exp Eye Res. 1967 Jul;6(3):219-26 6029412 Klin Monbl Augenheilkd. 1966;149(6):847-58 (...) Communications. Action of Atromid-S (clofibrate) on intra-ocular pressure. 4972749 1969 01 25 2018 11 13 0007-1161 52 11 1968 Nov The British journal of ophthalmology Br J Ophthalmol Communications. Action of Atromid-S (clofibrate) on intra-ocular pressure. 793-800 Gloster J J Hartley R E RE Perkins E S ES eng Journal Article England Br J Ophthalmol 0421041 0007-1161 0 Anticholesteremic Agents 0 Butyrates 0 Carbonic Anhydrase Inhibitors C24W7J5D5R Androsterone O3FX965V0I Acetazolamide IM

1968 The British journal of ophthalmology

191. [Experiences with timolol in treatment of glaucoma (author's transl)]. (Abstract)

%. Timolol was well tolerated in general, but 3 patients showed a superficial keratopathy. 30 other glaucoma patients with previously unsufficient pressure control received Timolol alone or in combination with a topical cholinergic agent or/and a systematic carbonic anhydrase inhibitor. The results are presented in detail. (...) [Experiences with timolol in treatment of glaucoma (author's transl)]. Timolol is a beta-adrenergic blocking agent that produces a significant decrease in intraocular pressure. Timolol ophthalmic solution 0,25% and 0,5% was compared to pilocarpine 1%, 2% and 4% in a randomized, double-masked study involving 40 patients with primary open angle glaucoma or ocular hypertension. Each patient was followed for 6 months. Timolol lowered the 1OP 30% compared to the pretreatment pressure, Pilocarpine 20

1978 Klinische Monatsblatter fur Augenheilkunde Controlled trial quality: uncertain

192. Retinitis Pigmentosa

with a hereditary syndrome may wish to seek genetic counseling before having children. Treatment Vitamin A palmitate Omega-3 fatty acids Lutein plus zeaxanthin Carbonic anhydrase inhibitors for cystoid macular edema Intraocular computer chip implants There is no way to reverse damage caused by retinitis pigmentosa, but vitamin A palmitate 15,000 IU po once/day may help slow disease progression in some patients. Patients taking vitamin A palmitate should have regular liver function tests. Dietary supplementation (...) with an omega-3 fatty acid (eg, docosahexaenoic acid) and an oral preparation of lutein plus zeaxanthin may also slow the rate of vision loss. Vision decreases as the macula becomes increasingly involved and can evolve to legal blindness. For patients with cystoid macular edema, carbonic anhydrase inhibitors given orally (eg, acetazolamide ) or topically (eg, dorzolamide ) may yield mild vision improvement. For patients with total or near total vision loss, epiretinal and subretinal computer chip implants

2013 Merck Manual (19th Edition)

193. Primary Open-Angle Glaucoma

be the initial treatment if IOP is extremely high, the patient does not wish to use or has trouble adhering to drug therapy, or if there is significant visual field damage at presentation. Drug therapy Multiple drugs are available (see Table: ). Topical agents are preferred. The most popular are prostaglandin analogs, followed by beta-blockers (particularly timolol ). Other drugs include alpha- 2 -selective adrenergic agonists, carbonic anhydrase inhibitors, and cholinergic agonists. Oral carbonic anhydrase (...) /day–bid Metipranolol 1 drop once/day–bid Carbonic anhydrase inhibitors (oral or IV) Acetazolamide 125–250 mg po qid (or 500 mg po bid using extended-release capsules) or 500 mg IV single dose Decrease aqueous production Used as adjunctive therapy Cause fatigue, altered taste, anorexia, depression, paresthesias, electrolyte abnormalities, kidney calculi, and blood dyscrasias Possibly nausea, diarrhea, weight loss Methazolamide 25–50 mg po bid–tid Carbonic anhydrase inhibitors (topical) Brinzolamide

2013 Merck Manual (19th Edition)

194. Ocular tolerance and efficacy of short-term tamponade with double filling of polydimethyloxane and perfluoro-n-octane Full Text available with Trip Pro

. The mean postoperative IOP was 19.7 mm Hg (11-32 mm Hg); nine cases (30.0%) developed an IOP increase that was treated with topical drops and/or systemic carbonic anhydrase inhibitors. The electroretinogram (ERG) and the bright flash electroretinogram (bf ERG) parameters showed a statistically significant difference of means between 4- and 8-week follow-up visits.Our experience with double filling in selected cases of retinal detachment has been positive. No electroretinographic signs of retinal (...) for an average of 23 (standard deviation 2.2) days. The follow-up visits were scheduled 1 week, 1 month, and 3 months after surgery. The main outcome measures were visual acuity, intraocular pressure (IOP), PVR reproliferation, and electrophysiological parameters.The primary success rate was 80% (24/30). Fourteen patients (46.7%) had a postoperative improvement in visual acuity, 12 patients (40.0%) maintained their preoperative visual acuity, and four patients (13.3%) experienced a reduction in visual acuity

2011 Clinical ophthalmology (Auckland, N.Z.) Controlled trial quality: uncertain

195. Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada

Hypertension Glaucoma Glaucoma, Open-Angle Ocular Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Timolol Brimonidine Tartrate, Timolol Maleate Drug Combination Maleic acid Brinzolamide Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Enzyme Inhibitors Carbonic Anhydrase Inhibitors Adrenergic alpha-2 Receptor Agonists (...) : July 1, 2014 Last Update Posted : July 1, 2014 Sponsor: Alcon Research Information provided by (Responsible Party): Alcon Research Study Details Study Description Go to Brief Summary: The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior brimonidine 0.2%/timolol 0.5% fixed combination (COMBIGAN®) therapy in patients with open-angle glaucoma or ocular hypertension and uncontrolled intraocular pressure (IOP). Condition or disease Intervention

2011 Clinical Trials

196. Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome

Pathologic Processes Ocular Motility Disorders Cranial Nerve Diseases Nervous System Diseases Eye Diseases Brinzolamide Carbonic Anhydrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action (...) Testing of Binocular Best Corrected Visual Acuity In The Nystagmus Null Zone The Validated Amblyopia & Strabismus Ocular Motor Questionnaire Eye Movement Recording Data Analysis of The Nystagmus Waveform Safety will be evaluated by: Ocular signs and symptoms Visual acuity (uncorrected and best corrected) Slit lamp exam and Intraocular Pressure Systemic signs and symptoms Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 5

2011 Clinical Trials

197. Patient Preference Comparison of AZARGA Versus COSOPT

Glaucoma, Open-Angle Ocular Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Ophthalmic Solutions Timolol Dorzolamide Brinzolamide Pharmaceutical Solutions Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) regimen of intraocular pressure-lowering (IOP) medication within 30 days of Screening Visit. IOP considered safe (in the opinion of the Investigator) in both eyes in such a way that assures clinical stability of vision and the optic nerve throughout the study period. IOP between 19 and 35 millimeters mercury (mmHg) in at least one eye (study eye). Willing to discontinue the use of all other ocular drugs (prescribed and over-the-counter) prior to receiving the screening dose during the Screening Visit

2011 Clinical Trials

198. Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension

laser surgery within the past 3 months. Intraocular surgery within the past 3 months. Best-corrected visual acuity score worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen, 0.60 logMAR or 0.25 decimal). History of, or current clinically relevant or progressive retinal disease in either eye. History of, or current other severe ocular pathology (including severe dry eye) in either eye, that would preclude the administration of a topical carbonic anhydrase inhibitor (CAI (...) Additional relevant MeSH terms: Layout table for MeSH terms Hypertension Glaucoma Glaucoma, Open-Angle Ocular Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases Ophthalmic Solutions Timolol Brinzolamide Pharmaceutical Solutions Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme

2011 Clinical Trials

199. Circadian Rhythms of Aqueous Humor Dynamics When Using Brimonidine in Humans With Ocular Hypertension

completed studies of day and night differences in aqueous humor dynamics in patients treated with drugs from three different classes that include a prostaglandin analog, a beta blocker and a carbonic anhydrase inhibitor. The current study is designed to elucidate the physiological mechanisms driving the efficacy of brimonidine, an alpha 2 adrenergic agonist, throughout the 24-hour period, i.e. circadian rhythms in aqueous humor dynamics. Based on what the investigators know of 24 hour IOPs this drug (...) Description: Currently, the only effective treatment to prevent disease progression is lowering of the intraocular pressure (IOP).2 Usually, clinical IOP measurements are performed during the day with little information collected on nocturnal IOP. A recent surge of interest in nocturnal IOPs stems from the hypothesis that significant glaucomatous damage may occur at night.4,5 In response, some investigators have advocated particular classes of glaucoma medications based on their nocturnal IOP effects.6-8

2011 Clinical Trials

200. Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

alpha-Agonists Adrenergic Agonists Carbonic Anhydrase Inhibitors Enzyme Inhibitors (...) for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Diagnosis of ocular hypertension or glaucoma in each eye Requires IOP-lowering treatment in both eyes Exclusion Criteria: Use of dorzolamide or carbonic anhydrase within 4 weeks Any other active ocular disease other than ocular hypertension or glaucoma (eg, uveitis, ocular infections or severe dry eye) Required chronic use

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>